Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of oral MK-0616 in adults with hypercholesterolemia
MOH_2023-08-08_012803Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and familial hypercholesterolemia (FH) comparing MK-0616 with Placebo (2 arms). Primary endpoints: Mean percent change in LDL-C from baseline at Week 24 and Safety and tolerability of MK-0616. Started Jun 2023; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on MOH_2023-08-08_012803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-08_012803.